GTCBio's Antibody Partnering & Technology Summit, to be held this October 29-30, 2009 in San Francisco, CA, provides a unique look at the antibody field while equally balancing business (e.g., M&A) and research & development related content. This exclusive antibody partnering conference is specifically designed to provide an intimate environment for those who want to network and collaborate with high-level executives. You will meet with top companies dynamically seeking the scientific and business tactics necessary for accelerating their antibody drug discovery and development. Without a doubt, this novel, hybrid-content conference will augment your opportunities for successful partnering and deal-making in 2010 and beyond.
Click here to register: 10% Discount by Sept 29, 2009
Submit an Abstract by September 30th, 2009 for a chance to give an oral presentation in front of your colleagues and peers. Click here for submission!
------------------------------------------------------------------------------Conference Sessions:
I: The Effect of Biosimilars: Roadmap to the Future
Panel Discussion: The Effect of Biosimilars: Roadmap to the Future
II: Opportunities for Antibody Partnering and Licensing
Panel Discussion: Opportunities for Antibody Partnering and Licensing
III: Antibody Mergers and Acquisitions
Panel Discussion: Antibody Merges and Acquisitions
IV: Novel and Next Generation Antibody Technologies
Panel Discussion: Novel and Next Generation Antibody Technologies
Register 2, the 3rd person goes free!
Click here for details https://gtcbio.com/userPart/GTCbio_Conference_Registration_Form.pdf.
PLENARY KEYNOTE:
Stan Yakatan
Chairman and Chief Executive Officer
Katan Associates
Distinguished Presenters & Advisors
Juan Almagro, Antibody Design Group Head, Johnson & Johnson
Matthias Birkhoff, Vice President - Pharma Division, Pfeiffer Group
Edward Tobinick, University of California, Los Angeles
Edward Maggio, President & Chief Executive Officer, Aegis Therapeutics
Doug Axelrod, Chief Medical Officer, Ambrx
James Hodge, Senior Scientist, NIH
Bruce Morimoto, Vice President, Drug Development, Allon Therapeutics
Paul Watt, Chief Science Officer, Phylogica
Mary Wloch, Associate Director, Vaccinology, Vical
Nils Lonberg, Senior Vice President & Scientific Director, Medarex
